# Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Source: https://onco.cc/trials/nct06391892/  
OnCo record `nct06391892` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by Elisabethinen Hospital, now recruiting.

## Summary

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery is a phase 3, interventional study registered as NCT06391892 by Elisabethinen Hospital, with a registry enrolment figure of 100 participants, started 2024-01-11 and due to reach its primary completion in 2025-12-31. Interventions recorded: Neoadjuvant chemotherapy instead of upfront surgery; Upfront surgery. Conditions listed: Pancreatic Cancer; Circulating Tumor Cell; Predictive Cancer Model. Primary outcome: DFS. Pancreatic eligibility wording from the registry: "* localized pancreatic cancer to go for upfront surgery". Sites: Austria. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: LIQUIPANC
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06391892
- Phase: 3
- Setting: Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery
- Sponsor: Elisabethinen Hospital
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06391892: https://clinicaltrials.gov/study/NCT06391892

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06391892.json